Lyme disease is caused by the spirochete Borrelia burgdorferi. This zoonosis is the most prevalent vector borne infectious disease in the United States and Europe and it continues to grow geographically. The enzootic cycle of this pathogen requires that Ixodes spp. acquire B. burgdorferi from infected wildlife reservoirs and transmit it to other uninfected wildlife. At present, there are no effective measures to control B. burgdorferi; there is no human vaccine available, and, existing vector control measures are generally not acceptable to the public. However, if B. burgdorferi could be eliminated from its reservoir hosts and from the ticks that feed on them, the enzootic cycle would be broken, and the incidence of Lyme disease would decrease. To accomplish this, we developed an OspA-based bait vaccine and demonstrated that, in the Lyme disease mouse model, ad libidum feeding induced systemic anti-OspA IgG and protected all vaccinated mice from B. burgdorferi infection after tick challenge. In addition, these anti-OspA antibodies cleared B. burgdorferi from the tick vector. Thus, this bait vaccine is a good candidate to break the enzootic cycle of this pathogen. The major goal of this Phase I SBIR proposal is to test a bait vaccine by ad libidum feeding of the natural host reservoir of this spirochete, the white-footed mouse, Peromyscus leucopus. After treatment, we will assess vaccine efficacy by analyzing B. burgdorferi infection prevalence of the host and of the tick vector. We will carry out experiments both in the laboratory and in the wild. The fieldwork component of this project will be performed at the Institute for Ecosystem Studies (IES) in Millbrook, NY. In a subsequent Phase II SBIR proposal, we would expand our field studies to span the two-year life cycle of the tick vector and assess different vehicles for bait delivery. Lyme disease is the most prevalent vector borne infectious disease in the United States and Europe, and its geographical range is expanding. One way to reduce the incidence of Lyme disease is to eliminate B. burgdorferi from its reservoir and/or from the ticks that feed on them, breaking the mouse-tick cycle. The goal of this Phase I SBIR proposal is to test a bait vaccine against B. burgdorferi via ad libidum feeding of the major host reservoir of this spirochete, the white-footed mouse. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AI072810-01
Application #
7218534
Study Section
Special Emphasis Panel (ZRG1-IMM-K (12))
Program Officer
Breen, Joseph J
Project Start
2007-09-15
Project End
2009-08-31
Budget Start
2007-09-15
Budget End
2008-08-31
Support Year
1
Fiscal Year
2007
Total Cost
$299,996
Indirect Cost
Name
Biopeptides, Inc.
Department
Type
DUNS #
140704532
City
East Setauket
State
NY
Country
United States
Zip Code
11733
Gomes-Solecki, Maria; Richer, Luciana (2018) Recombinant E. coli Dualistic Role as an Antigen-adjuvant Delivery Vehicle for Oral Immunization. Methods Mol Biol 1690:347-357
Richer, Luciana Meirelles; Brisson, Dustin; Melo, Rita et al. (2014) Reservoir targeted vaccine against Borrelia burgdorferi: a new strategy to prevent Lyme disease transmission. J Infect Dis 209:1972-80
Meirelles Richer, Luciana; Aroso, Miguel; Contente-Cuomo, Tania et al. (2011) Reservoir targeted vaccine for lyme borreliosis induces a yearlong, neutralizing antibody response to OspA in white-footed mice. Clin Vaccine Immunol 18:1809-16
del Rio, Beatriz; Seegers, Jos F M L; Gomes-Solecki, Maria (2010) Immune response to Lactobacillus plantarum expressing Borrelia burgdorferi OspA is modulated by the lipid modification of the antigen. PLoS One 5:e11199
del Rio, Beatriz; Fuente, Jesus Lajara; Neves, Vera et al. (2010) Platform technology to deliver prophylactic molecules orally: an example using the Class A select agent Yersinia pestis. Vaccine 28:6714-22
Ivanova, Larisa; Christova, Iva; Neves, Vera et al. (2009) Comprehensive seroprofiling of sixteen B. burgdorferi OspC: implications for Lyme disease diagnostics design. Clin Immunol 132:393-400
del Rio, Beatriz; Dattwyler, Raymond J; Aroso, Miguel et al. (2008) Oral immunization with recombinant lactobacillus plantarum induces a protective immune response in mice with Lyme disease. Clin Vaccine Immunol 15:1429-35